The Proposed Drug Conditional Approval Pathway and Responses From Cancer Survivors

This survey study assesses understanding of and responses to the proposed US Food and Drug Administration conditional drug approval pathway among individuals who have received prior treatment for cancer or are currently undergoing treatment.

Corresponding Author: Mark E. Fleury, PhD, American Cancer Society Cancer Action Network, 655 15th St NW, Ste 503, Washington, DC 20005 (mark.fleury@cancer.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.